Effect of Common Genetic Variants on the Risk of Cirrhosis in Non-alcoholic Fatty Liver Disease During 20 years of Follow-up

Overview

Journal Liver Int

Specialty Gastroenterology

Date 2022 Sep 27

PMID 36166317

Authors

Magnus Holmer

Mattias Ekstedt

Patrik Nasr

Robin Zenlander

Axel Wester

Federica Tavaglione

Stefano Romeo

Stergios Kechagias

Per Stal

Hannes Hagstrom

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Several genotypes associate with a worse histopathological profile in patients with non-alcoholic fatty liver disease (NAFLD). Whether genotypes impact long-term outcomes is unclear. We investigated the importance of PNPLA3, TM6SF2, MBOAT7 and GCKR genotype for the development of severe outcomes in NAFLD.

Method: DNA samples were collected from 546 patients with NAFLD. Advanced fibrosis was diagnosed by liver biopsy or elastography. Non-alcoholic steatohepatitis (NASH) was histologically defined. Additionally, 5396 controls matched for age, sex and municipality were identified from population-based registers. Events of severe liver disease and all-cause mortality were collected from national registries. Hazard ratios (HRs) adjusted for age, sex, body mass index and type 2 diabetes were estimated with Cox regression.

Results: In NAFLD, the G/G genotype of PNPLA3 was associated with a higher prevalence of NASH at baseline (odds ratio [OR] 3.67, 95% CI = 1.66-8.08), but not with advanced fibrosis (OR 1.81, 95% CI = 0.79-4.14). After up to 40 years of follow-up, the PNPLA3 G/G genotype was associated with a higher rate of severe liver disease (adjusted hazard ratio [aHR] 2.27, 95% CI = 1.15-4.47) compared with the C/C variant. NAFLD patients developed cirrhosis at a higher rate than controls (aHR 9.00, 95% CI = 6.85-11.83). The PNPLA3 G/G genotype accentuated this rate (aHR 23.32, 95% = CI 9.14-59.47). Overall mortality was not affected by any genetic variant.

Conclusion: The PNPLA3 G/G genotype is associated with an increased rate of cirrhosis in NAFLD. Our results suggest that assessment of the PNPLA3 genotype is of clinical relevance in patients with NAFLD to individualize monitoring and therapeutic strategies.

Citing Articles

Early childhood adiposity, lifestyle and gut microbiome are linked to steatotic liver disease development in adolescents.

Cai C, Zhang Z, Alberti G, Pereira A, De Barbieri F, Garcia C Int J Obes (Lond). 2025; .

PMID: 40075127 DOI: 10.1038/s41366-025-01737-1.

Global Epidemiology and Implications of I148M Variant in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-analysis.

Souza M, Al-Sharif L, Diaz I, Mantovani A, Villela-Nogueira C J Clin Exp Hepatol. 2025; 15(3):102495.

PMID: 39882540 PMC: 11773032. DOI: 10.1016/j.jceh.2024.102495.

Genetic predisposition of metabolic dysfunction-associated steatotic liver disease: a population-based genome-wide association study.

Wang S, Wang C, Cheng Y, Chen C, Hsieh T, Wang C Hepatol Int. 2025; .

PMID: 39755997 DOI: 10.1007/s12072-024-10769-0.

Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease.

Raverdy V, Tavaglione F, Chatelain E, Lassailly G, De Vincentis A, Vespasiani-Gentilucci U Nat Med. 2024; 30(12):3624-3633.

PMID: 39653777 PMC: 11645276. DOI: 10.1038/s41591-024-03283-1.

Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD.

Petta S, Armandi A, Bugianesi E Liver Int. 2024; 45(3):e16133.

PMID: 39412170 PMC: 11815615. DOI: 10.1111/liv.16133.

References

Petit J, Masson D, Guiu B, Rollot F, Duvillard L, Bouillet B . GCKR polymorphism influences liver fat content in patients with type 2 diabetes. Acta Diabetol. 2015; 53(2):237-42. DOI: 10.1007/s00592-015-0766-4. View

. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64(6):1388-402. DOI: 10.1016/j.jhep.2015.11.004. View

Raja A, Ciociola E, Ahmad I, Dar F, Naqvi S, Moaeen-Ud-Din M . Genetic Susceptibility to Chronic Liver Disease in Individuals from Pakistan. Int J Mol Sci. 2020; 21(10). PMC: 7278956. DOI: 10.3390/ijms21103558. View

Dongiovanni P, Anstee Q, Valenti L . Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des. 2013; 19(29):5219-38. PMC: 3850262. DOI: 10.2174/13816128113199990381. View

Brooke H, Talback M, Hornblad J, Johansson L, Ludvigsson J, Druid H . The Swedish cause of death register. Eur J Epidemiol. 2017; 32(9):765-773. PMC: 5662659. DOI: 10.1007/s10654-017-0316-1. View

Oniki K, Saruwatari J, Izuka T, Kajiwara A, Morita K, Sakata M . Influence of the PNPLA3 rs738409 Polymorphism on Non-Alcoholic Fatty Liver Disease and Renal Function among Normal Weight Subjects. PLoS One. 2015; 10(7):e0132640. PMC: 4511733. DOI: 10.1371/journal.pone.0132640. View

Holmer M, Ekstedt M, Nasr P, Zenlander R, Wester A, Tavaglione F . Effect of common genetic variants on the risk of cirrhosis in non-alcoholic fatty liver disease during 20 years of follow-up. Liver Int. 2022; 42(12):2769-2780. PMC: 9828463. DOI: 10.1111/liv.15438. View

Ludvigsson J, Andersson E, Ekbom A, Feychting M, Kim J, Reuterwall C . External review and validation of the Swedish national inpatient register. BMC Public Health. 2011; 11:450. PMC: 3142234. DOI: 10.1186/1471-2458-11-450. View

De Franchis R . Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015; 63(3):743-52. DOI: 10.1016/j.jhep.2015.05.022. View

10.

Laugesen K, Ludvigsson J, Schmidt M, Gissler M, Valdimarsdottir U, Lunde A . Nordic Health Registry-Based Research: A Review of Health Care Systems and Key Registries. Clin Epidemiol. 2021; 13:533-554. PMC: 8302231. DOI: 10.2147/CLEP.S314959. View

11.

Pingitore P, Romeo S . The role of PNPLA3 in health and disease. Biochim Biophys Acta Mol Cell Biol Lipids. 2018; 1864(6):900-906. DOI: 10.1016/j.bbalip.2018.06.018. View

12.

Singh S, Allen A, Wang Z, Prokop L, Murad M, Loomba R . Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2014; 13(4):643-54.e1-9. PMC: 4208976. DOI: 10.1016/j.cgh.2014.04.014. View

13.

Sookoian S, Flichman D, Garaycoechea M, Gazzi C, San Martino J, Castano G . Lack of evidence supporting a role of TMC4-rs641738 missense variant-MBOAT7- intergenic downstream variant-in the Susceptibility to Nonalcoholic Fatty Liver Disease. Sci Rep. 2018; 8(1):5097. PMC: 5865142. DOI: 10.1038/s41598-018-23453-9. View

14.

Liu Y, Reeves H, Burt A, Tiniakos D, McPherson S, Leathart J . TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. 2014; 5:4309. PMC: 4279183. DOI: 10.1038/ncomms5309. View

15.

Unalp-Arida A, Ruhl C . Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population. Hepatology. 2019; 71(3):820-834. DOI: 10.1002/hep.31032. View

16.

Anstee Q, Darlay R, Cockell S, Meroni M, Govaere O, Tiniakos D . Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. J Hepatol. 2020; 73(3):505-515. DOI: 10.1016/j.jhep.2020.04.003. View

17.

De Vincentis A, Tavaglione F, Spagnuolo R, Pujia R, Tuccinardi D, Masciana G . Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank. Int J Obes (Lond). 2021; 46(3):486-493. PMC: 8573310. DOI: 10.1038/s41366-021-01015-w. View

18.

Hagstrom H, Nasr P, Ekstedt M, Hammar U, Stal P, Hultcrantz R . Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017; 67(6):1265-1273. DOI: 10.1016/j.jhep.2017.07.027. View

19.

Ludvigsson J, Otterblad-Olausson P, Pettersson B, Ekbom A . The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009; 24(11):659-67. PMC: 2773709. DOI: 10.1007/s10654-009-9350-y. View

20.

Austin P, Lee D, Fine J . Introduction to the Analysis of Survival Data in the Presence of Competing Risks. Circulation. 2016; 133(6):601-9. PMC: 4741409. DOI: 10.1161/CIRCULATIONAHA.115.017719. View